Orlicz-Sobolev nematic elastomers

We extend the existence theorems in Barchiesi et al. (2017), for models of nematic elastomers and magnetoelasticity, to a larger class in the scale of Orlicz spaces. These models consider both an elastic term where a polyconvex energy density is composed with an unknown state variable defined in the deformed configuration, and a functional corresponding to the nematic energy (or the exchange and magnetostatic energies in magnetoelasticity) where the energy density is integrated over the deformed configuration. In order to obtain the desired compactness and lower semicontinuity, we show that the regularity requirement that maps create no new surface can still be imposed when the gradients are in an Orlicz class with an integrability just above the space dimension minus one

Partial Regularity for Minimizers of Discontinuous Quasiconvex Integrals with general growth

We prove the partial Hölder continuity for minimizers of quasiconvex functionals F(u):=∫Ωf(x,u,Du)dx, where f satisfies a uniform VMO condition with respect to the x-variable and is continuous with respect to u. The growth condition with respect to the gradient variable is assumed a general one

Surgical procedures as a major risk factor for chronic hepatitis C virus infection in Italy: Evidence from a case-control study

n/

Scattering from Singular Potentials in Quantum Mechanics

In non-relativistic quantum mechanics, singular potentials in problems with spherical symmetry lead to a Schrodinger equation for stationary states with non-Fuchsian singularities both as r tends to zero and as r tends to infinity. In the sixties, an analytic approach was developed for the investigation of scattering from such potentials, with emphasis on the polydromy of the wave function in the r variable. The present paper extends those early results to an arbitrary number of spatial dimensions. The Hill-type equation which leads, in principle, to the evaluation of the polydromy parameter, is obtained from the Hill equation for a two-dimensional problem by means of a simple change of variables. The asymptotic forms of the wave function as r tends to zero and as r tends to infinity are also derived. The Darboux technique of intertwining operators is then applied to obtain an algorithm that makes it possible to solve the Schrodinger equation with a singular potential containing many negative powers of r, if the exact solution with even just one term is already known.Comment: 19 pages, plain Tex. In this revised version, the analysis of Eq. (5.29) has been amended, and an appendix has been added for completenes

Virological and clinical characteristics of hepatitis delta virus in South Asia

<p>Abstract</p> <p>Background & Aims</p> <p>There is a paucity of data on the impact of hepatitis D virus (HDV) in patients with hepatitis B virus (HBV) infection from South Asia. We studied the impact of HDV co-infection on virological and clinical characteristics.</p> <p>Methods</p> <p>We collected data of 480 patients with HBsAg positive and a detectable HBV DNA PCR, who presented to the Aga Khan University, Karachi and Isra University in Hyderabad, Pakistan in the last 5 years. HDV co-infection was diagnosed on the basis of anti-HDV. ALT, HBeAg, HBeAb and HBV DNA PCR quantitative levels were checked in all patients. We divided all patients into two groups based on anti-HDV, and compared their biochemical, serological & virological labs and clinical spectrum. Clinical spectrum of disease included asymptomatic carrier (AC), chronic active hepatitis (CAH), immuno-tolerant phase (IP), and compensated cirrhosis (CC).</p> <p>Results</p> <p>HDV co-infection was found in 169 (35.2%). There were 164 (34.6%) HBeAg positive and 316 (65.4%) HBeAg negative patients. Mean ALT level was 66 ± 73 IU. 233 (48.5%) had raised ALT. HBV DNA level was ≥ 10e5 in 103(21.5%) patients. Overall, among HBV/HDV co-infection, 146/169 (86.4%) had suppressed HBV DNA PCR as compared to 231/311 (74.3%) patients with HBV mono-infection; p-value = 0.002. Among HBeAg negative patients 71/128(55.5%) had raised ALT levels among HBV/HDV co-infection as compared to 71/188 (37.8%) with HBV mono-infection (p-value = 0.002); levels of HBV DNA were equal in two groups; there were 27/128 (21%) patients with CC among HBV/HDV co-infection as compared to 23 (12%) in HBV mono-infection (p-value = 0.009); there were less AC (p-value = 0.009) and more CAH (p-value = 0.009) among HBV/HDV co-infection patients. Among HBeAg positive patients, serum ALT, HBV DNA levels and the spectrum of HBV were similar in the two groups.</p> <p>Conclusions</p> <p>HBV/HDV co-infection results in the suppression of HBV DNA. A fair proportion of HBV/HDV co-infected patients with HBeAg negative have active hepatitis B infection and cirrhosis as compared to those with mono-infection.</p

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

Background Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. Methods Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. Results HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. Conclusion Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission